

## Acknowledgements

---

I am grateful to Professor Para Chandrasoma, Director, Department of Anatomical Pathology at Los Angeles County, University of Southern California Medical Center, Los Angeles, USA for providing me the opportunity to train in the field of immunohistochemistry. It enabled me to set up the first immunohistochemistry laboratory in Colombo and to use this methodology in this research..

I am indebted to Prof A. H. Sheriffdeen for having introduced me to this field of breast research, for excellent guidance and support and also for providing me access to his patients.

I express my gratitude to Professor L. R. Amarasekera, Head, Department of Pathology, University of Colombo for the encouragement extended.

I am much grateful to Drs Neil Thalagala at the Epidemiology unit, Colombo and M. W. Gunathunga at Department of Community Medicine, University of Colombo for helping me with the statistical analysis of results.

I am thankful to Dr J. Balawardana, Oncologist at the Cancer Institute Maharagama for the valuable information and guidance provided.

I appreciate the technical support extended by Mrs Kokila Wijesinghe, at Department of Pathology, Faculty of Medicine, Colombo.

My gratitude is also extended to Dr Navoda Attapattu who acted as an unofficial research assistant and helped me with collection of data.

Lastly I am thankful to the National Science Foundation for awarding this research grant, which enabled me to carry out this study.

# Contents

---

Page No.

Abstract.....	i
Acknowledgement .....	iii
List of Figures and Plates .....	vi
List of Tables.....	vii

## CHAPTER 1

1.0 Introduction .....	1
------------------------	---

## CHAPTER 2

2.0 Objectives .....	3
----------------------	---

## CHAPTER 3

3.0 Methodology .....	4
3.1 Study type.....	4
3.2 Study population and sample.....	4
3.3 Preliminary arrangements and collection of data .....	4

## CHAPTER 4

4.0 Analysis of data .....	7
----------------------------	---

## CHAPTER 5

5.0 Results .....	13
-------------------	----

**CHAPTER 6**

6.0 Discussion and conclusions ..... 23

**CHAPTER 7**

7.0 Recommendations ..... 31

**REFERENCES** ..... 32

## List of Figures and Plates

---

	Page No.
Figure 4.1 - Algorithmic representation of method of categorization	9
Plate 4.1 - Macroscopic appearance of a breast carcinoma	11
Plate 4.2 - Deposits of breast carcinoma in a lymph node – low power view (10x10) haematoxylin and eosine stained sections	11
Plate 4.3 - A well differentiated breast carcinoma (Nottingham grade 1) High power view (10x40) haematoxylin and eosine stained sections	12
Plate 4.4 - A poorly differentiated breast carcinoma (Nottingham grade 3) High power view (10x40) haematoxylin and eosine stained sections	12
Figure 5.1 - Macroscopic tumour size	14
Figure 5.2 - FNA Diagnosis	14
Figure 5.3 - Tumour type by histological assessment	15
Figure 5.4 - Tumour grading	15
Figure 5.5 - Auxillary lymph node status	16
Plate 5.1 - A breast carcinoma with strong nuclear positivity for oestrogen receptors Low power view (10x10)	20
Plate 5.2 - A breast carcinoma with strong nuclear positivity for oestrogen receptors High power view (10x40)	20
Plate 5.3 - A breast carcinoma with strong cell membrane positivity for Her2neu Low power view (10x10)	21
Plate 5.4 - A breast carcinoma with strong cell membrane positivity for Her2neu High power view (10x40)	21
Plate 5.5 - A breast carcinoma with strong nuclear positivity for progesterone receptors medium power view (10x20)	22
Plate 5.6 - A breast carcinoma with strong nuclear positiviiy for p53 medium power view (10x20)	22

## List of Tables

---

Table	Page No.	
4.1	Categorization of patients in to low and high risk groups for recurrent disease by considering macroscopic size of the tumour	7
4.2	Categorization of patients in to low and high risk groups for recurrent disease by considering histological grade of the tumour.	8
4.3	Categorization in to low and high risk groups considering the immune marker status	10
5.1	Frequency distribution of age in 10 year groups	13
5.2	Frequency distribution of ER status	16
5.3	Frequency distribution of Her2neu status	17
5.4	Association between immune marker status and clinical and morphological features and FNAB diagnosis	17
5.5	Agreement between the risk of recurrent disease assessed by tumour size and the risk assessed by ER status	18
5.6	Agreement between the risk of recurrent disease assessed by histological grade and the risk assessed by ER status	18
5.7	Agreement between the risk of recurrent disease assessed by tumour size and the risk assessed by Her2neu status.	18
5.8	Agreement between the risk of recurrent disease assessed by histological grade and the risk assessed by Her2neu status.	19
5.9	Agreement between the metastatic risk assessed by clinical and morphological features and the risk assessed by ER status.	19
5.10	Agreement between the metastatic risk assessed by clinical and morphological features and the risk assessed by Her 2 Neu status	19